• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    January 8, 2021 - Coronavirus (COVID-19) Update: January 8, 2021

    1/8/21 3:42:09 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary
    Get the next $RH alert in real time by email
    For Immediate Release:
    January 08, 2021

    The U.S. Food and Drug Administration (FDA) continued to take action in the ongoing response to the COVID-19 pandemic:

    • The FDA alerted clinical laboratory staff and health care providers that genetic variants of SARS-CoV-2 may lead to false negative results with molecular tests for SARS-CoV-2. The Letter to Clinical Laboratory Staff and Health Care Providers includes important information about potential false negative results with molecular tests, including:
      • Details on the effect of genetic variants on test performance.
      • Recommendations for clinical laboratory staff and health care providers.
      • Actions the FDA has taken.  
      • Instructions for reporting problems with a test. 
    • This week, the FDA posted a new webpage, Moderna COVID-19 Vaccine Frequently Asked Questions. Questions cover specifics, such as what data did the FDA review when deciding whether to authorize the vaccine for emergency use, how well the vaccine prevents COVID-19, and more.
    • A U.S. District Court in Georgia granted a consent decree of permanent injunction against Fusion Health and Vitality LLC, Fusion Ionz LLC and Matthew Ryncarz for violating federal law by distributing products containing vitamin D and hordenine HCl, as preventions or treatments for COVID-19. The order of permanent injunction that the Court issued permanently prohibits the defendants from, among other things, selling or distributing unapproved new drugs or misbranded drugs with claims that the products can cure, mitigate, treat or prevent diseases in people, including COVID-19.  In addition, the injunction permanently prohibits defendants from selling or distributing dietary supplements containing hordenine HCl because hordenine HCl is an unsafe food additive. In May, FDA issued a warning letter to the defendants for fraudulently promoting violative products on a number of websites. In the warning letter, the FDA requested that they immediately correct their violations, which they did not do.  
      • “Americans expect and deserve medical treatments that have been scientifically proven to be safe and effective. Making claims that unproven drugs can cure or prevent diseases, including COVID-19, places consumers’ health at risk,” said FDA Chief Counsel Stacy Amin. “We remain committed to pursuing and taking swift action against those who attempt to subvert the regulatory functions of the FDA by repeatedly disregarding the law and distributing unapproved products.” 
      • The FDA is particularly concerned that fraudulent products that claim to cure, mitigate, treat or prevent serious diseases like COVID-19 may cause consumers to delay or stop appropriate medical treatment, leading to serious and life-threatening harm. The FDA reminds the public to seek medical help from their health care providers and urges people to talk to their health care provider about treatment options.
    • Testing updates:
      • As of today, 311 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 235 molecular tests and sample collection devices, 64 antibody tests, and 12 antigen tests. There are 32 molecular authorizations that can be used with home-collected samples. There is one molecular prescription at-home test, one antigen prescription at-home test, and one over-the-counter (OTC) at-home antigen test.
         

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

    ###


    Inquiries

    Media:
    Courtney Rhodes
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

    Related Information

    Related Information

    •    COVID-19 Vaccines
    •    Coronavirus Disease 2019 (COVID-19)


    Get the next $RH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RH

    DatePrice TargetRatingAnalyst
    4/3/2025$410.00 → $130.00Buy → Underperform
    BofA Securities
    4/3/2025$200.00Buy → Neutral
    Citigroup
    4/3/2025$420.00 → $280.00Outperform
    Telsey Advisory Group
    3/24/2025$500.00 → $420.00Outperform
    Telsey Advisory Group
    1/30/2025$261.00 → $374.00Sell → Neutral
    Goldman
    1/13/2025$435.00 → $530.00Equal-Weight → Overweight
    Morgan Stanley
    1/8/2025$383.00 → $515.00Equal Weight → Overweight
    Barclays
    12/19/2024$485.00 → $500.00Market Perform → Outperform
    Telsey Advisory Group
    More analyst ratings

    $RH
    SEC Filings

    See more
    • RH filed SEC Form 8-K: Leadership Update

      8-K - RH (0001528849) (Filer)

      4/28/25 4:15:23 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • RH filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - RH (0001528849) (Filer)

      4/8/25 7:30:10 AM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • SEC Form 10-K filed by RH

      10-K - RH (0001528849) (Filer)

      4/2/25 4:59:08 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary

    $RH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RH downgraded by BofA Securities with a new price target

      BofA Securities downgraded RH from Buy to Underperform and set a new price target of $130.00 from $410.00 previously

      4/3/25 12:54:00 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • RH downgraded by Citigroup with a new price target

      Citigroup downgraded RH from Buy to Neutral and set a new price target of $200.00

      4/3/25 8:16:49 AM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • Telsey Advisory Group reiterated coverage on RH with a new price target

      Telsey Advisory Group reiterated coverage of RH with a rating of Outperform and set a new price target of $280.00 from $420.00 previously

      4/3/25 8:00:10 AM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary

    $RH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by RH

      SC 13G/A - RH (0001528849) (Subject)

      11/14/24 5:05:51 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by RH

      SC 13G/A - RH (0001528849) (Subject)

      11/14/24 4:15:30 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by RH

      SC 13G/A - RH (0001528849) (Subject)

      11/12/24 10:34:15 AM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary

    $RH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN & CEO Friedman Gary G bought $9,999,978 worth of shares (46,274 units at $216.10), increasing direct ownership by 1% to 3,351,337 units (SEC Form 4)

      4 - RH (0001528849) (Issuer)

      6/27/24 7:47:18 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary

    $RH
    Leadership Updates

    Live Leadership Updates

    See more
    • RH Announces the Appointment of Jarrett Stuhl as Chief Real Estate & Development Officer

      RH (NYSE:RH) today announced the appointment of Jarrett Stuhl as Chief Real Estate & Development Officer. Mr. Stuhl will lead Real Estate Development, Architecture & Design for all the Company's brands, concepts and facilities, domestically and internationally. Mr. Stuhl will report to RH's Chairman and Chief Executive Officer, Gary Friedman. Prior to joining RH, Mr. Stuhl spent nine years bringing Soho House & Co. Inc into new markets across the world. Ascending through the company, and lastly serving as Chief Operating Officer for The Americas, Mr. Stuhl had responsibility for real estate, development, membership, communications, food & beverage and hotel operations. Gary Friedman,

      1/18/24 8:32:00 AM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • Remitly Appoints Two New Members to its Board of Directors

      SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Remitly Global, Inc. (NASDAQ:RELY) ("Remitly"), a leading digital financial services provider for immigrants and their families, today announced the appointments of Phyllis Campbell and Ryno Blignaut to its Board of Directors.  "We are delighted to welcome Phyllis and Ryno to Remitly's Board of Directors," said Matt Oppenheimer, CEO of Remitly. "They each bring with them a wealth of knowledge and leadership experience to complement our existing team of accomplished directors. I'm grateful for their passion and dedication to our customer-centric vision for the future of digital financial services."  Campbell and Blignaut bring decades of leaders

      4/6/23 9:00:00 AM ET
      $RELY
      $RH
      Business Services
      Consumer Discretionary
      Other Specialty Stores

    $RH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RH Provides Clarifications Related to the Reciprocal Tariffs Announced on April 2, 2025

      The Company Also Introduces Fiscal 2025 Free Cash Flow Outlook RH (NYSE:RH) provided the following clarifications today based on the market volatility related to the reciprocal tariffs announced on April 2, 2025. The Company has been operating with 25% tariffs from China since the last Trump administration and has successfully resourced the majority of its China production to Vietnam at significantly better than pre-tariff landed China pricing. In addition, the Company has successfully resourced a meaningful amount of its China production to its own factory in North Carolina. As discussed during the Company's fourth quarter earnings call on April 2, 2025, RH believes President Trump is u

      4/4/25 5:58:00 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • RH Reports Fourth Quarter and Fiscal 2024 Results

      RH (NYSE:RH) has released its financial results for the fourth quarter and fiscal year 2024 ended February 1, 2025, in a shareholder letter from Chairman and Chief Executive Officer Gary Friedman, available on the Investor Relations section of its website at ir.rh.com. As previously announced, RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) today. The live conference call may be accessed by dialing 800.715.9871 or 646.307.1963 for international callers (conference ID: 8284432). The call and replay can also be accessed via audio webcast at ir.rh.com. ABOUT RH RH (NYSE:RH) is a curator of design, taste and style in the luxury

      4/2/25 4:05:00 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • RH to Report Fourth Quarter and Fiscal Year 2024 Financial Results on April 2, 2025

      RH (NYSE:RH) today announced that it will report financial results for the fourth quarter and fiscal year 2024 ended February 1, 2025, on Wednesday, April 2, 2025 after market close. RH's fourth quarter and fiscal year 2024 financial results press release will include a shareholder letter from Chairman and Chief Executive Officer, Gary Friedman, highlighting the Company's continued evolution and recent performance. The shareholder letter and financial results will be posted to the Company's investor relations website at ir.rh.com. RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) on April 2, 2025. The live conference call may be

      3/24/25 6:45:00 AM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary

    $RH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

      Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

      1/18/21 5:24:40 AM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

      Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

      1/18/21 5:24:40 AM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

      Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/15/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

      1/15/21 11:16:15 AM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary

    $RH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CHIEF ACCOUNTING OFFICER Hargarten Christina

      4 - RH (0001528849) (Issuer)

      4/14/25 9:30:09 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • SEC Form 4 filed by Officer Chaya Eri

      4 - RH (0001528849) (Issuer)

      4/14/25 9:30:07 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • SEC Form 4 filed by Officer Duban Stefan

      4 - RH (0001528849) (Issuer)

      4/14/25 9:30:10 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary

    $RH
    Financials

    Live finance-specific insights

    See more
    • RH Reports Fourth Quarter and Fiscal 2024 Results

      RH (NYSE:RH) has released its financial results for the fourth quarter and fiscal year 2024 ended February 1, 2025, in a shareholder letter from Chairman and Chief Executive Officer Gary Friedman, available on the Investor Relations section of its website at ir.rh.com. As previously announced, RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) today. The live conference call may be accessed by dialing 800.715.9871 or 646.307.1963 for international callers (conference ID: 8284432). The call and replay can also be accessed via audio webcast at ir.rh.com. ABOUT RH RH (NYSE:RH) is a curator of design, taste and style in the luxury

      4/2/25 4:05:00 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • RH to Report Fourth Quarter and Fiscal Year 2024 Financial Results on April 2, 2025

      RH (NYSE:RH) today announced that it will report financial results for the fourth quarter and fiscal year 2024 ended February 1, 2025, on Wednesday, April 2, 2025 after market close. RH's fourth quarter and fiscal year 2024 financial results press release will include a shareholder letter from Chairman and Chief Executive Officer, Gary Friedman, highlighting the Company's continued evolution and recent performance. The shareholder letter and financial results will be posted to the Company's investor relations website at ir.rh.com. RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) on April 2, 2025. The live conference call may be

      3/24/25 6:45:00 AM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary
    • RH Reports Third Quarter Fiscal 2024 Results

      RH (NYSE:RH) has released its financial results for the third quarter ended November 2, 2024, in a shareholder letter from Chairman and Chief Executive Officer Gary Friedman, available on the Investor Relations section of its website at ir.rh.com. As previously announced, RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) today. The live conference call may be accessed by dialing 800.715.9871 or 646.307.1963 for international callers (conference ID: 3000234). The call and replay can also be accessed via audio webcast at ir.rh.com. ABOUT RH RH (NYSE:RH) is a curator of design, taste and style in the luxury lifestyle market. T

      12/12/24 4:05:00 PM ET
      $RH
      Other Specialty Stores
      Consumer Discretionary